Aquestive Therapeutics (AQST) Inventory Average (2018 - 2026)

Aquestive Therapeutics' Inventory Average history runs 9 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• On a quarterly basis, Inventory Average rose 7.5% year-over-year to $7.1 million in Q1 2026; TTM through Mar 2026 was $7.1 million, a 7.5% increase from a year earlier, with the FY2025 full-year figure at $6.1 million, down 4.68% from the prior year.
• Inventory Average climbed to $7.1 million in Q1 2026 per AQST's latest filing, from $7.0 million in the prior quarter.
• Across five years, Inventory Average topped out at $8.0 million in Q3 2025 and bottomed at $4.3 million in Q1 2022.
• The 5-year median for Inventory Average is $6.6 million (2025), against an average of $6.6 million.
• Across the five-year window, Inventory Average surged 105.77% in 2022 and retreated 8.69% in 2025, its largest moves.
• Year by year, Inventory Average stood at $6.3 million in 2022, then gained by 10.74% to $6.9 million in 2023, then retreated by 5.65% to $6.5 million in 2024, then gained by 7.56% to $7.0 million in 2025, then grew by 1.3% to $7.1 million in 2026.
• Per Business Quant, the three latest AQST Inventory Average figures stand at $7.1 million (Q1 2026), $7.0 million (Q4 2025), and $8.0 million (Q3 2025).